Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children's Oncology Group Study.

ABSTRACT:

Importance

Variability in prescribed doses of 6-mercaptopurine (6MP) and lack of adherence to a 6MP treatment regimen could result in intra-individual variability in systemic exposure to 6MP (measured as erythrocyte thioguanine nucleotide [TGN] levels) in children with acute lymphoblastic leukemia (ALL). The effect on relapse risk of this variability is unknown.

Objective

To determine the effect of high intra-individual variability of 6MP systemic exposure on relapse risk in children with ALL.

Design, setting, and participants

We used a prospective longitudinal design (Children's Oncology Group study [COG-AALL03N1]) to monitor 6MP and disease relapse in 742 children with ALL in ambulatory care settings of 94 participating institutions from May 30, 2005, to September 9

SUBMITTER: Bhatia S 

PROVIDER: S-EPMC4561178 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature